Table S1 (DOC) Acknowledgments SRD5A3 oligo probe 1. In EMSA, biotin-labeled oligo probe 1 was incubated alone (lane 1), with LNCaP cell nuclear extract (lane 2), with LNCaP cell nuclear extract and unlabeled oligo probe 1 (lane 3), or with LNCaP cell nuclear extract plus unlabeled mutated oligo probe 1 (lane 4). (TIF) Characteristics of the cell lines. We thank Dr. Sue-Hwa Lin and Miao Huang (MD Anderson) for providing the BPH-1-GFP and BPH-1-AR cells and Dr. Robert Reiter References 1. Fitzpatrick JM, Schulman C, Zlotta AR, Schroder FH (2009) Prostate cancer: a serious disease suitable for prevention. BJU Int 103: 864–870. 2. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665– 1671. 3. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253–8261. 4. Zhu YS, Imperato-McGinley JL (2009) 5a-Reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci 1155: 43–56. 5. Wilson EM, French FS (1976) Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem 251: 5620–5629. 6. Wilbert DM, Griffin JE, Wilson JD (1983) Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 56: 113–120. 7. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB (2003) Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 57: 134–139. 8. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, et al. (2005) Differential alterations in 5a-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63: 231–239. 9. Bjelfman C, Soderstrom TG, Brekkan E, Norlen BJ, Egevad L, et al. (1997) Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab 82: 2210–2214. 10. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, et al. (2008) Novel 5a-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 99: 81–86. 11. Titus MA, Mohler JL (2009) 5a-Reductase Isozymes in Castration-Recurrent Prostate Cancer. Androgen Action in Prostate Cancer, Springer New York: Part 2, 175–185. 12. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, et al. (2011) 5alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate 71: 1033–1046. 13. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, et al. (2010) SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 142: 203–217. 14. Morava E, Wevers RA, Cantagrel V, Hoefsloot LH, Al-Gazali L, et al. (2010) A novel cerebello-ocular syndrome with abnormal glycosylation due to abnormal- ities in dolichol metabolism. Brain 133: 3210–3220. 15. Kahrizi K, Hu CH, Garshasbi M, Abedini SS, Ghadami S, et al. (2011) Next generation sequencing in a family with autosomal recessive Kahrizi syndrome (OMIM 612713) reveals a homozygous frameshift mutation in SRD5A3. Eur J Hum Genet 19: 115–117. 16. Stoner E (1990) The clinical development of a 5a-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 37: 375–378. 17. Tian G, Mook RA, Jr., Moss ML, Frye SV (1995) Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1–4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochem- istry 34: 13453–13459. 18. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224. 19. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, et al. (2004) Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 172: 1314–1317. 20. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, et al. (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: 1192–1202. 21. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT (2006) Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12: 4072–4079. Androgen Regulation of 5a-Reductase Isoenzymes (University of California, Los Angeles) for providing the LAPC-4 cells. We also thank Karen Phillips, ELS (MD Anderson), for editing the manuscript. Further, we thank the Characterized Cell Line Core at MD Anderson Cancer Center for performing the STR DNA fingerprinting of cell lines. Author Contributions Conceived and designed the experiments: JL GBM JK. Performed the experiments: JL JFL. Analyzed the data: JL ZD ZW SNM NMN GBM CJL JK. Contributed reagents/materials/analysis tools: SNM NMN GBM CJL JK. Wrote the paper: JL JK. 22. Makridakis N, Reichardt JKV (2005) Pharmacogenetic analysis of human steroid 5a reductase type II: comparison of finasteride and dutasteride. J Mol Endocrinol 34: 617–623. 23. Makridakis NM, di Salle E, Reichardt JKV (2000) Biochemical and pharmacogenetic dissection of human steroid 5a-reductase type II. Pharmaco- genetics 10: 407–413. 24. George FW (1997) Androgen metabolism in the prostate of the finasteride- treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract. Endocrinology 138: 871–877. 25. Steiner JF (1996) Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30: 16–27. 26. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R (2008) Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 72: 808–812. 27. George FW, Russell DW, Wilson JD (1991) Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5a-reductase. Proc Natl Acad Sci U S A 88: 8044–8047. 28. Pratis K, O’Donnell L, Ooi GT, Stanton PG, McLachlan RI, et al. (2003) Differential regulation of rat testicular 5a-reductase type 1 and 2 isoforms by testosterone and FSH. J Endocrinol 176: 393–403. 29. Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW, et al. (1994) Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 152: 433–437. 30. Zhou Z, Speiser PW (1999) Regulation of HSD17B1 and SRD5A1 in lymphocytes. Mol Genet Metab 68: 410–417. 31. Melcangi RC, Poletti A, Cavarretta I, Celotti F, Colciago A, et al. (1998) The 5alpha-reductase in the central nervous system: expression and modes of control. J Steroid Biochem Mol Biol 65: 295–299. 32. Torres JM, Ortega E (2003) Precise quantitation of 5a-reductase type 1 mRNA by RT-PCR in rat liver and its positive regulation by testosterone and dihydrotestosterone. Biochem Biophys Res Commun 308: 469–473. 33. Torres JM, Ortega E (2003) Differential regulation of steroid 5a-reductase isozymes expression by androgens in the adult rat brain. Faseb J 17: 1428–1433. 34. El-Awady MK, El-Garf W, El-Houssieny L (2004) Steroid 5a reductase mRNA type I is differentially regulated by androgens and glucocorticoids in the rat liver. Endocr J 51: 37–46. 35. Romano P, Manniello A, Aresu O, Armento M, Cesaro M, et al. (2009) Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Res 37: D925–932. 36. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, et al. (2011) Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient’s tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71: 846–856. 37. Dai WS, Kuller LH, LaPorte RE, Gutai JP, Falvo-Gerard L, et al. (1981) The epidemiology of plasma testosterone levels in middle-aged men. Am J Epidemiol 114: 804–816. 38. Reddy GK (2004) Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer. Clin Prostate Cancer 2: 209–211. 39. Wilson JD (1996) Role of dihydrotestosterone in androgen action. Prostate Suppl 6: 88–92. 40. Noss KR, Wolfe SA, Grimes SR (2002) Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 285: 247–256. 41. Qi W, Gao S, Wang Z (2008) Transcriptional regulation of the TGF-b1 promoter by androgen receptor. Biochem J 416: 453–462. 42. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, et al. (2008) Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 61: 448–454. 43. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, et al. (2005) Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14: 2257–2260. PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e28840